- Home
- MBLY vs HCM Comparison
MBLY vs HCM Comparison
Compare MBLY & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBLY | HCM |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Israel | Hong Kong |
| Employees | 4200 | 1796 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBLY | HCM |
|---|---|---|
| Price | $8.23 | $11.16 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 20 | 1 |
| Target Price | ★ $14.13 | $13.75 |
| AVG Volume (30 Days) | ★ 8.7M | 50.3K |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,894,000,000.00 | N/A |
| Revenue This Year | $4.91 | $20.60 |
| Revenue Next Year | $13.94 | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 14.51 | N/A |
| 52 Week Low | $6.47 | $9.77 |
| 52 Week High | $15.81 | $18.79 |
Technical Indicators
Market Signals| Indicator | MBLY | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 51.63 |
| Support Level | $7.66 | $10.83 |
| Resistance Level | $10.01 | $11.80 |
| Average True Range (ATR) | 0.59 | 0.21 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 35.04 | 40.10 |
Price Performance
Historical ComparisonAbout MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.